Literature DB >> 34230025

Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients.

Sangwoo S Kim1, Whitney A Sumner1, Sayuri Miyauchi1, Ezra E W Cohen2, Joseph A Califano1,3, Andrew B Sharabi4.   

Abstract

The role of B cells in the tumor microenvironment and B-cell-mediated antitumor immune responses remains relatively understudied. Recent seminal studies have discovered that B cells and associated tertiary lymphoid structures correlate with responses to checkpoint blockade immunotherapy and are prognostic for overall survival of cancer patients. B-cell subsets have remarkable functional diversity and include professional antigen-presenting cells, regulatory cells, memory populations, and antibody-producing plasma cells. Importantly, secreted antibodies can independently activate innate immune responses and induce the cancer immunity cycle. Thus, B cells and B-cell-mediated antibody responses comprise the largely underappreciated second arm of the adaptive immune system and certainly deserve further attention in the field of oncology. Here, we review the known functions of B cells in the tumor microenvironment, the contribution of B cells to the antitumor activity of immunotherapies, and the role of B cells in the overall survival of cancer patients. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34230025      PMCID: PMC8976464          DOI: 10.1158/1078-0432.CCR-21-0697

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

Review 1.  Immunoglobulin class-switch DNA recombination: induction, targeting and beyond.

Authors:  Zhenming Xu; Hong Zan; Egest J Pone; Thach Mai; Paolo Casali
Journal:  Nat Rev Immunol       Date:  2012-06-25       Impact factor: 53.106

2.  FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.

Authors:  Rony Dahan; Emanuela Sega; John Engelhardt; Mark Selby; Alan J Korman; Jeffrey V Ravetch
Journal:  Cancer Cell       Date:  2015-10-12       Impact factor: 31.743

3.  FcRgamma activation regulates inflammation-associated squamous carcinogenesis.

Authors:  Pauline Andreu; Magnus Johansson; Nesrine I Affara; Ferdinando Pucci; Tingting Tan; Simon Junankar; Lidiya Korets; Julia Lam; David Tawfik; David G DeNardo; Luigi Naldini; Karin E de Visser; Michele De Palma; Lisa M Coussens
Journal:  Cancer Cell       Date:  2010-02-04       Impact factor: 31.743

4.  Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells.

Authors:  Stefanie Lindner; Karen Dahlke; Kai Sontheimer; Magdalena Hagn; Christof Kaltenmeier; Thomas F E Barth; Thamara Beyer; Frank Reister; Dorit Fabricius; Ramin Lotfi; Oleg Lunov; G Ulrich Nienhaus; Thomas Simmet; Rolf Kreienberg; Peter Möller; Hubert Schrezenmeier; Bernd Jahrsdörfer
Journal:  Cancer Res       Date:  2013-02-05       Impact factor: 12.701

5.  IL-7 specifies B cell fate at the common lymphoid progenitor to pre-proB transition stage by maintaining early B cell factor expression.

Authors:  Kazu Kikuchi; Hirotake Kasai; Akiko Watanabe; Anne Y Lai; Motonari Kondo
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

6.  The humoral immune system has a key prognostic impact in node-negative breast cancer.

Authors:  Marcus Schmidt; Daniel Böhm; Christian von Törne; Eric Steiner; Alexander Puhl; Henryk Pilch; Hans-Anton Lehr; Jan G Hengstler; Heinz Kölbl; Mathias Gehrmann
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

7.  Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity.

Authors:  Yiwen Lu; Qiyi Zhao; Jian-You Liao; Erwei Song; Qidong Xia; Jiayao Pan; Yihong Li; Jiaqian Li; Boxuan Zhou; Yingying Ye; Can Di; Shubin Yu; Yunjie Zeng; Shicheng Su
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

8.  Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.

Authors:  Ariel E Marciscano; Ali Ghasemzadeh; Thomas R Nirschl; Debebe Theodros; Christina M Kochel; Brian J Francica; Yuki Muroyama; Robert A Anders; Andrew B Sharabi; Esteban Velarde; Wendy Mao; Kunal R Chaudhary; Matthew G Chaimowitz; John Wong; Mark J Selby; Kent B Thudium; Alan J Korman; David Ulmert; Daniel L J Thorek; Theodore L DeWeese; Charles G Drake
Journal:  Clin Cancer Res       Date:  2018-06-13       Impact factor: 12.531

9.  B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.

Authors:  Johannes Griss; Wolfgang Bauer; Christine Wagner; Martin Simon; Minyi Chen; Katharina Grabmeier-Pfistershammer; Margarita Maurer-Granofszky; Florian Roka; Thomas Penz; Christoph Bock; Gao Zhang; Meenhard Herlyn; Katharina Glatz; Heinz Läubli; Kirsten D Mertz; Peter Petzelbauer; Thomas Wiesner; Markus Hartl; Winfried F Pickl; Rajasekharan Somasundaram; Peter Steinberger; Stephan N Wagner
Journal:  Nat Commun       Date:  2019-09-13       Impact factor: 14.919

10.  Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma.

Authors:  Dominik Pretscher; Luitpold V Distel; Gerhard G Grabenbauer; Michael Wittlinger; Maike Buettner; Gerald Niedobitek
Journal:  BMC Cancer       Date:  2009-08-22       Impact factor: 4.430

View more
  8 in total

1.  Intratumoral immunotherapy relies on B and T cell collaboration.

Authors:  Idit Sagiv-Barfi; Debra K Czerwinski; Tanaya Shree; Julian J K Lohmeyer; Ronald Levy
Journal:  Sci Immunol       Date:  2022-05-27

Review 2.  B-Cell-Based Immunotherapy: A Promising New Alternative.

Authors:  Sneh Lata Gupta; Naeem Khan; Srijani Basu; Vijay Soni
Journal:  Vaccines (Basel)       Date:  2022-05-31

3.  A comprehensive characterization of alternative splicing events related to prognosis and the tumor microenvironment in lung adenocarcinoma.

Authors:  Shouzheng Ma; Jun Zhu; Mengmeng Wang; Tenghui Han; Jianfei Zhu; Runmin Jiang; Tao Jiang
Journal:  Ann Transl Med       Date:  2022-04

4.  A novel immune-related ceRNA network that predicts prognosis and immunotherapy response in lung adenocarcinoma.

Authors:  Wei-Jing Gong; Tao Zhou; San-Lan Wu; Yi-Fei Huang; Li-Ping Xiang; Jia-Qiang Xu; Yong Han; Yong-Ning Lv; Fang Zeng; Yu Zhang
Journal:  Ann Transl Med       Date:  2021-09

5.  Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.

Authors:  Fei Yang; Gui-Li Xu; Jin-Tao Huang; Yu Yin; Wei Xiang; Bin-Yan Zhong; Wan-Ci Li; Jian Shen; Shuai Zhang; Jun Yang; Hong Peng Sun; Wan-Sheng Wang; Xiao-Li Zhu
Journal:  Front Immunol       Date:  2022-02-18       Impact factor: 7.561

6.  B cell receptor signaling strength modulates cancer immunity.

Authors:  Jian Ye; Peter P Lee
Journal:  J Clin Invest       Date:  2022-03-15       Impact factor: 14.808

Review 7.  Neutrophils: Musketeers against immunotherapy.

Authors:  Kashif Rafiq Zahid; Umar Raza; Soumya Tumbath; Lingxiang Jiang; Wenjuan Xu; Xiumei Huang
Journal:  Front Oncol       Date:  2022-08-25       Impact factor: 5.738

8.  B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis.

Authors:  Anqi Lin; Jianbo Fang; Quan Cheng; Zaoqu Liu; Peng Luo; Jian Zhang
Journal:  J Inflamm Res       Date:  2022-09-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.